VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                          

 

4th August 2013 - New research

CLINICAL TRIAL OF AFQ056 FOR DYSKINESIA

Movement Disorders [2013] July 11 [Epub ahead of print] (Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.) Complete abstract

AFQ056 is a new glutamate receptor antagonist being developed for the treatment of L-dopa induced dyskinesia. Dyskinesia is a difficulty or distortion in performing voluntary movements, which often occurs as a side effect of long term therapy with L-dopa. For more information go to Dyskinesia. People with Parkinson's Disease were given either 20mg, 50mg, 100mg, 150mg, or 200mg daily for 12 weeks. The primary outcome in order to assess the effect on dyskinesia was the modified Abnormal Involuntary Movements Scale.

Patients taking 200mg AFQ056 daily demonstrated significant improvements on the modified Abnormal Involuntary Movements Scale. There was a dose-response relationship, with 200 mg daily demonstrating the greatest effect. However, no significant changes were observed on the 26-item Parkinson's Disease Dyskinesia Scale or the Patient's / Clinician's Global Impression of Change. Unified Parkinson's Disease Rating Scale part III scores were not significantly changed, indicating no worsening of motor symptoms. The most common adverse events were dizziness, hallucination, fatigue, nasopharyngitis, diarrhea, and insomnia. These results can guide the slection of doses for future clinical trials. For a printable version of this article click here. For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
2006-2013  Viartis
 
2015-01-05 16:01:13
 
[email protected]